COMPASS PATHWAYS PLC (CMPS)

Company Profile

Compass Pathways Plc is an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 114 full-time employees. The company went IPO on 2020-09-18. The firm is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The firm has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The firm's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The firm is also running a Phase II clinical trial of COMP360 psilocybin therapy for anorexia nervosa and post-traumatic stress disorder (PTSD). The firm is also developing its investigational COMP360 psilocybin therapy for the treatment of a range of mental health conditions, with an initial focus on TRD.

Company Info

COMPASS PATHWAYS PLC

3Rd Floor, 1 Ashley Road

Altrincham CHESHIRE WA14 2DT

P: 17166766461

CEO: George Goldsmith

Employees: 114

Website: https://compasspathways.com/